Communicable Disease Epidemiology and Immunization Section

401 5th Avenue, Suite 1250 Seattle, WA 98104

206-296-4774 Fax 206-296-4803

TTY Relay: 711

www.kingcounty.gov/health



Health Advisory: *Candida auris* – Increased Transmission in U.S. Healthcare Facilities, December 20, 2022

Action Requested:

- Be aware that an emerging, often multidrug-resistant fungal pathogen, <u>Candida auris (C. auris)</u>, is spreading <u>westward across the U.S.</u> and causing outbreaks in healthcare facilities.
 - As of December 2022, no *C. auris* cases have been reported in Washington State, but healthcare transmission has occurred in California, Oregon (1,2 – references below), Nevada (3), the Mid-West, and East Coast.
- Inquire about high-risk exposures in all newly admitted patients and consider *C. auris* screening in patients at high risk for *C. auris*, including those who have had:
 - Close contact in a healthcare setting to someone diagnosed with *C. auris* infection or colonization.
 - o An overnight stay in a healthcare facility outside the U.S. or in a region within the <u>U.S. with</u> documented *C. auris* cases in the previous year.
- Immediately report any suspected or confirmed *C. auris* cases or outbreaks to Public Health by calling 206-296-4774.
 - C. auris becomes a notifiable condition in WA as of January 1, 2023.
- Consultation with an infectious disease specialist and Public Health is highly recommended when C. auris colonization or infection is suspected to ensure appropriate testing and treatment.
- Coordinate C. auris screening and testing with Public Health by calling 206-296-4774.
- Be aware that *C. auris* can be misidentified through commercial laboratory testing and <u>specific</u> technology is needed for correct identification.
- Be aware that in addition to the screening recommendations above, Public Health will soon begin
 offering proactive C. auris screening to residents at a local long-term ventilator capable healthcare
 facility. These are the types of settings which have been most heavily impacted in California and
 East Coast outbreaks.
- Ensure appropriate infection prevention and control practices:
 - o Patients with suspected or confirmed *C. auris* in healthcare facilities should be managed using contact precautions and placed in a single room whenever possible.
 - When C. auris is suspected, use healthcare disinfectants that are effective against C. auris.
 - o Remain vigilant for any increase in infections due to unusual *Candida* species in a patient care unit, including from urine specimens, and consider *C. auris*.
 - Reinforce and audit core infection prevention practices in healthcare facilities.
 - <u>Communicate information</u> about colonization or infection with *C. auris* during care transitions within and transfers between healthcare settings. Consider using the CDC Interfacility transfer form.
 - For laboratories working with suspect or confirmed *C. auris*, be aware of <u>safety</u> <u>considerations</u> including recommended PPE, disinfection, and disposal.

Communicable Disease Epidemiology and Immunization Section

401 5th Avenue, Suite 1250 Seattle, WA 98104

206-296-4774 Fax 206-296-4803

TTY Relay: 711

www.kingcounty.gov/health



Background

Since its discovery in 2009, *C. auris* has emerged globally as a life-threatening, highly transmissible, often multidrug-resistant yeast. In the past year, CDC has published several reports of ongoing transmission of highly resistant strains of *C. auris* in United States' healthcare facilities, particularly in units caring for patients recovering from COVID-19 (4,5,6). Patients with long-term acute care and indwelling devices are at highest risk for acquisition. International healthcare is often the initial source of introduction of *C. auris* to a region. Subsequent healthcare transmission may occur due to shedding in the healthcare environment, resistance of *C. auris* to standard healthcare disinfectants, and lapses in infection control practices.

As of December 20, 2022, *C. auris* has not been detected in Washington but represents a serious threat to vulnerable patients. This <u>map</u> has details about where cases have been identified within the U.S. WA DOH performs special surveillance for *C. auris* by screening isolates submitted from high risk patients and sentinel lab submissions of non-albicans *Candida* species to the WA Public Health Laboratory for species identification.

References

- 1. Oregon Health Authority News Release. OHA investigating state's first cases of Candida auris infection. Dec 28, 2021. https://content.govdelivery.com/accounts/ORDHS/bulletins/3030234
- 2. Oregon Health Authority News Release. No other cases of Candida auris infection found at Salem Hospital. Jan 6, 2022. https://content.govdelivery.com/accounts/ORDHS/bulletins/3045cee
- 3. Causey K. Candida auris technical bulletin April 22, 2022. https://dpbh.nv.gov/uploadedFiles/dpbhnvgov/content/Resources/TB C-auris 042222.pdf
- 4. Prestel C, Anderson E, Forsberg K, et al. <u>Candida auris</u> Outbreak in a COVID-19 Specialty Care Unit <u>Florida, July—August 2020</u>. <u>MMWR Morb Mortal Wkly</u> Rep 2021;70:56–57. DOI
- 5. Lyman M, Forsberg K, Reuben J, et al. <u>Notes from the Field: Transmission of Pan-Resistant and Echinocandin-Resistant Candida auris in Health Care Facilities Texas and the District of Columbia, January—April 2021. *MMWR Morb Mortal Wkly* Rep 2021;70:1022—1023. DOI.</u>
- 6. Adams E, Quinn M, Tsay S, et al. <u>Candida auris in Healthcare Facilities</u>, <u>New York</u>, <u>USA</u>, <u>2013-2017</u>. *Emerg Infect Dis*. 2018;24(10):1816-1824. DOI.

Resources

- <u>Candida auris resources</u>, WA Department of Health
- Candida auris testing information, WA Department of Health
- Antimicrobial Products Registered with EPA for Claims Against Candida auris, Environmental Protection Agency
- Candida auris- Information for Laboratorians and Health Professionals, CDC
- General Information about Candida auris, CDC